Peloton Therapeutics, Inc. announced that it has received $150,000,000 in its series E round of funding led by new investor RA Capital Management, LLC on February 20, 2019. The transaction involved participation from new investors Eventide Asset Management, LLC, Biotechnology Value Fund L.P.; a fund managed by BVF Partners LP, OrbiMed Advisors, L.L.C., EcoR1 Capital, LLC, Vida Ventures, Curative Ventures, Driehaus Capital Management LLC, and existing investors The Column Group LLC, Nextech Invest Ltd., Topspin Partners LBO, LP, Tichenor Ventures, LLC, and Foresite Capital Management, LLC.